Autolus Therapeutics Price to Book Ratio 2018-2021 | AUTL

Historical price to book ratio values for Autolus Therapeutics (AUTL) over the last 10 years. The current price to book ratio for Autolus Therapeutics as of October 22, 2021 is 1.39.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Autolus Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 5.58 1.43
2021-06-30 6.64 $3.90 1.70
2021-03-31 5.73 $5.72 1.00
2020-12-31 8.94 $4.01 2.23
2020-09-30 11.64 $4.53 2.57
2020-06-30 16.03 $4.96 3.23
2020-03-31 5.99 $5.50 1.09
2019-12-31 13.20 $5.67 2.33
2019-09-30 12.42 $5.99 2.07
2019-06-30 16.10 $6.63 2.43
2019-03-31 31.47 $5.43 5.80
2018-12-31 32.84 $5.79 5.67
2018-09-30 30.67 0.00
2018-06-30 26.79 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.406B $0.002B
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76